Viewing nowValsartan Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

MFDS item code 200808199 · Notified 2008.07.28
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to lower blood pressure in patients with essential hypertension. It also helps improve symptoms in heart failure patients who are intolerant to ACE inhibitors. After a myocardial infarction, it is effective in reducing the mortality risk in patients with left ventricular dysfunction. This drug plays an important role in protecting cardiovascular health and increasing patient survival rates; therefore, it is used for essential hypertension, certain types of heart failure, and post-myocardial infarction management.
(Tablets) 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Adults: The recommended dose, regardless of sex or race, is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (75 years and older): Start treatment with this medicine at 40 mg once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Start treatment with this medicine at 40 mg once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with this medicine at 40 mg once daily. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with this medicine at 40 mg once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment No dose adjustment is necessary for creatinine clearance of 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus and newborn during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This drug should not be used in patients with certain conditions. For example, people allergic to this drug or its ingredients, pregnant or nursing women, patients with severe liver disease or cirrhosis, hereditary angioedema patients, severe renal impairment patients, primary hyperaldosteronism patients, and some patients with diabetes or severe renal impairment should not take this medication. Elderly patients, patients with hyperkalemia, patients with liver disease, patients with valvular heart disease, patients with cardiovascular disease, and patients with fluid depletion should exercise caution when taking this medication, and it is important to monitor for sudden drops in blood pressure during the initial phase of treatment. This drug lowers blood pressure but may cause side effects such as headaches, dizziness, cough, diarrhea, and fatigue. Adverse reactions have also been reported in patients with heart failure or after myocardial infarction. During treatment, blood pressure, kidney function, and potassium levels should be regularly monitored for any abnormalities. Care should be taken regarding interactions when taken with other antihypertensive drugs, diuretics, or potassium supplements. Caution is required as this drug may cause dizziness when driving or operating machinery. Women who are pregnant or planning to become pregnant should not take this medication, and nursing mothers are advised to discontinue breastfeeding while taking this drug. Safety and efficacy in children and adolescents under 18 years of age have not been sufficiently established, so use is not recommended. In case of overdose, serious hypotension or altered consciousness may occur, and immediate contact with a medical facility for appropriate measures is necessary. This medication should be kept out of reach of children, and it is safer not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from getting in, away from direct sunlight, and in a cool place below 30 degrees Celsius. This will help maintain the medication's effectiveness for a long time.
Light pink, bilaterally convex, round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.